Work

Abstract PS2-02-03: Real-world treatment patterns in 1954 US patients with HER2-negative early breast cancer and germline BRCA mutations (2021-2025)

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-02-03

Authors: S. Sardesai, M. Ru, X. Ma, C. Keane, J. Wang, M. Miranda, X. Xu, C. Isaacs

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, AstraZeneca (United States), Flatiron Health (United States), AstraZeneca (United Kingdom), Georgetown University, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129616687

Cites:

Cited by:

Related to: